Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Premier, Inc. to Divest Non-Healthcare GPO Operations for Approximately $800 Million in Cash: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Divest Non-Healthcare GPO Operations for Approximately $800 Million in Cash


Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-enabled healthcare improvement company, today announced that it has entered into a definitive agreement with OMNIA

LivaNova to Announce Second-Quarter 2023 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Second-Quarter 2023 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m

Convatec Group PLC: Holding(s) in Company
Convatec Group PLC: Holding(s) in Company
Convatec Group PLC: Holding(s) in Company
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A P

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Launches Off-the-Shelf Lentiviral Vector Packaging Plasmids


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the

Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase


Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital

Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase


Almirall S.A. (ALM) (the “Company”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “Capital Increase”) for

Annual General Shareholders’ Meeting 2023:
Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy


Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today

Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference:
Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference


Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf

New Study Shows That 84% of People With Diabetes Struggle With Mental Health1: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
New Study Shows That 84% of People With Diabetes Struggle With Mental Health1


As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health.1 The study, commissioned by DexCom, Inc.

NanoString Reports Inducement Grants Under Nasdaq Listing Rules: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Reports Inducement Grants Under Nasdaq Listing Rules


NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration


Charles River Laboratories International, Inc. (NYSE: CRL) and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal

EQS-News: Abivax stock included in MSCI Indexes
EQS-News: Abivax stock included in MSCI Indexes
EQS-News: Abivax stock included in MSCI Indexes
Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiencyhttps://www.cyansecurity.com/:
Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency


Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and

Dexcom to Host Investor Day on June 23, 2023: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom to Host Investor Day on June 23, 2023


DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations

Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener LabsPhoto, wide shot, wide-angle lens, soft focus,  IT consulting firm, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-uhXP0RHYYxDepjmHeSp1K8bF.png?st=2023-05-07T15%3A26%3A44Z&se=2023-05-07T17%3A26%3A44Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-07T16%3A18%3A55Z&ske=2023-05-08T16%3A18%3A55Z&sks=b&skv=2021-08-06&sig=4pcJOd8aEI1799liUV13F4ElqO7e4RZy8sa1PEeeNZA%3D
Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs


Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions

EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics


Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene